Detalhe da pesquisa
1.
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Cancer
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630908
2.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lancet Oncol
; 21(2): 207-221, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31859245
3.
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.
Clin Infect Dis
; 71(5): 1255-1262, 2020 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31769793
4.
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
Br J Haematol
; 170(1): 40-9, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25825041
5.
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.
Blood
; 122(4): 499-506, 2013 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-23692856
6.
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.
Blood
; 119(16): 3698-704, 2012 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22389254
7.
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.
Br J Haematol
; 163(3): 334-42, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24032456
8.
Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Jpn J Clin Oncol
; 43(5): 466-75, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23456745
9.
Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma.
CPT Pharmacometrics Syst Pharmacol
; 12(10): 1411-1424, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37465991
10.
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma.
Br J Haematol
; 157(4): 438-45, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22409295
11.
Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma.
CPT Pharmacometrics Syst Pharmacol
; 10(8): 851-863, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34076364
12.
Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
Clin Pharmacol Ther
; 110(5): 1282-1292, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34468979
13.
A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies.
Oncologist
; 15(9): 954-60, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20798192
14.
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
Haematologica
; 100(8): e311-4, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25769539
15.
A Phase 1 Study to Assess the Relative Bioavailability, Food Effect, and Safety of a Tablet Formulation of GSK2838232, a Novel HIV Maturation Inhibitor in Healthy Participants After Single and Repeated Doses.
Clin Pharmacol Drug Dev
; 9(8): 972-977, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32558338
16.
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
Blood Cancer J
; 10(10): 106, 2020 10 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33097687
17.
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
Clin Cancer Res
; 14(23): 7900-8, 2008 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19047120
18.
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.
Clin Cancer Res
; 13(11): 3276-85, 2007 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17545533
19.
The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects.
Pharmacol Res Perspect
; 6(4): e00408, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29930812
20.
Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
Clin Cancer Res
; 12(14 Pt 1): 4265-73, 2006 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16857801